Tissue repair: what the research shows now, and the horizon

How the body repairs itself, which peptides are studied, and the horizon as an outlook.

Peptalis: for laboratory research use only. Not for human use.

The first crash course named tissue repair and regeneration as one of the six research areas where peptides draw attention. This piece goes into that one area. The structure is deliberately twofold: first the foundation (what is factually known about tissue repair and what the research shows now) and then the horizon: what that may mean for the future, explicitly as an outlook. That separation is the difference between what has been demonstrated and what remains an open question.

Part A · The foundation

What is factually known about tissue repair, and what the research shows now.

Part 1

How the body repairs itself

Objective: After this part it is clear that tissue repair is a coordinated process, driven by signals between cells.

The body repairs itself continuously. A wound that closes is not a single event. It is a sequence of steps that follow one another.

Many cell types take part in those steps. Platelets, immune cells called macrophages, connective-tissue cells called fibroblasts, and the cells that form new blood vessels work after and alongside one another. That interplay is driven by signals that cells pass to one another.

One element recurs throughout: the formation of new blood vessels. That process is called angiogenesis, and it brings oxygen and building materials to the healing tissue.

Another element is the construction of a support structure. Cells lay down a network of, among other things, collagen, called the extracellular matrix: the material between the cells that gives tissue its strength.

In short. Tissue repair is a staged, directed process, not a single event. Signals between cells determine when each step takes place.

Part 2

Growth factors: the messengers of repair

Objective: After this part it is clear that many of the signals driving repair are proteins and peptides, and what that distinction means.

The signals from the previous part have a name. A large share of them are growth factors: proteins that prompt cells to divide, move or build.

Several families play a role. VEGF drives the formation of new blood vessels; PDGF, EGF, FGF and TGF-β are involved in, among other things, cell division, cell migration and the building of the matrix (Barrientos et al., 2008). These growth factors are proteins and peptides, the same kind of molecules the first course introduced as messengers.

An important distinction belongs here right away, because it is a common misconception. The fact that the body uses these proteins does not mean an administered protein does the same thing. Of the many growth factors, in fact only one fully completed a randomised clinical trial in the United States, as a drug for a specific wound type: PDGF-BB, under the name becaplermin (Barrientos et al., 2008).

That places three things side by side that must not be confused. An endogenous protein is biology; an approved drug is a regulated product with clinical evidence; and a research compound is a substance still under study. This piece keeps the three strictly separate.

In short. The messengers of repair are largely proteins and peptides. But endogenous biology, an approved drug and a research compound are three different things.

Part 3

Why this makes peptides interesting to study

Objective: After this part it is clear why the signalling role of peptides in repair raises an interesting research question.

A logical question follows from the previous parts. If the body drives repair with peptide signals, could synthetic peptides serve as a precise entry point for studying those processes?

That is a research question, not a conclusion. The appeal lies in the precision: a peptide with a known sequence is a defined substance, which can be deployed in a targeted way in a model.

That is exactly why this is an active research area. Researchers explore whether certain peptides can influence the steps from part 1 (cell migration, angiogenesis, matrix building) in a model.

What follows is how far that research has actually come. Because enthusiasm about a direction says nothing yet about the strength of the evidence.

In short. The signalling role of peptides makes tissue repair an interesting research area. An interesting question, however, is something other than a demonstrated outcome.

Part 4

What the research shows now

Objective: After this part it is clear which research peptides are studied in this area, and at what level the evidence stands for each.

A few peptides recur in this research area. Each comes with an honest description of the evidence level, because it differs greatly.

BPC-157 is studied in models for the repair of soft tissue, such as tendons and the digestive tract. The evidence is predominantly preclinical (cell culture and animal studies), and the mechanism of action remains unresolved after decades of research (Gwyer et al., 2019; Seiwerth et al., 2021). The first controlled study in humans, a phase 2 trial in a hamstring injury, started in early 2026.

Thymosin β4, often referred to in research as TB-500, has a better-understood mechanism. It binds the protein actin and, in lab and animal models, promotes the migration of cells and the formation of blood vessels (Malinda et al., 1997). The published human research, however, is limited and concentrated in ophthalmology: small phase 2 studies with eye drops for dry eye, with mixed outcomes (Sosne & Ousler, 2015; Sosne et al., 2015). That published human research also concerns thymosin β4 itself (as RGN-259); for TB-500, the injectable research form, there are no human studies of its own.

GHK-Cu, a copper-containing tripeptide, is an endogenous molecule whose levels decline with age. In cell culture and cosmetic studies, signals have been described around the building and breakdown of collagen (Pickart, 2008; Pickart et al., 2015). That evidence is limited and largely in vitro and cosmetic in nature, and the literature leans heavily on a single research group; controlled research into tissue repair in humans is absent.

In short. In this area there is a lot of preclinical and early research, and little strong human evidence. The level differs per compound and is named honestly here in each case.

Part 5

Reading the evidence honestly

Objective: After this part it is clear how the state of the evidence in this area can be read honestly.

The previous parts showed a recurring picture. Much of the research sits on the lower rungs of the evidence ladder from the first course.

That is exactly what the second crash course explained. Research in humans is expensive and slow, and for substances without patent protection large-scale research often does not get off the ground by itself.

Two things hold at once here, and neither may push out the other. The evidence is weighed honestly for what it is, often early and limited. And at the same time, ‘little studied’ is not read as ‘refuted’.

That is precision, not half-heartedness. An early finding is an open question: a reason to look further, not to draw a conclusion the evidence does not yet support.

In short. In this area the evidence is predominantly early. Naming that honestly, without reading it as rejection, is the only correct way to weigh it.

Part B · The horizon

What this research may mean for the future, explicitly as an outlook.

Part 6

What the future may bring

Objective: After this part it is clear what perspective this research area offers, explicitly as an outlook and not a promise.

This part is an outlook. It describes what could be if the early findings from the foundation are confirmed. Nothing below is a commitment, and nothing below describes an effect in humans or animals.

The appeal of this area can be stated well without promising anything. If peptides can be used as a precise entry point to repair processes, that would offer a fine-grained way to study those processes.

That perspective stands or falls with confirmation. The early signals from part 4 would have to hold up in larger, independent and preferably controlled studies before anything is settled.

It is exactly here that something fitting this platform lies. For patent-free, under-studied peptides, independent follow-up research can fill gaps that conventional funding leaves untouched. That is not a call to a product. It describes where the work lies.

And that, frankly, is what makes a research area worthwhile. Not the certainty of an outcome, but the clarity of a good, still-unanswered question.

Scientific references

All references are PubMed-indexed and verified (as of June 2026). According to PubMed.

  1. 01Barrientos S, et al. Growth factors and cytokines in wound healing. Wound Repair and Regeneration, 2008. Review PMID 19128254
  2. 02Malinda KM, et al. Thymosin β4 stimulates directional migration of human umbilical vein endothelial cells. FASEB Journal, 1997. Lab/dier PMID 9194528
  3. 03Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a Phase II, placebo-controlled clinical trial. Clinical Ophthalmology, 2015. Fase II RCT PMID 26056426
  4. 04Sosne G, et al. Thymosin beta 4 (RGN-259) improves the signs and symptoms of severe dry eye. Cornea, 2015. Fase II RCT PMID 25826322
  5. 05Gwyer D, et al. Gastric pentadecapeptide BPC 157 and its role in musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. Review PMID 30915550
  6. 06Seiwerth S, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology, 2021. Review PMID 34267654
  7. 07Pickart L. The human tripeptide GHK and tissue remodeling. Journal of Biomaterials Science Polymer Edition, 2008. Review · in-vitro PMID 18644225
  8. 08Pickart L, et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International, 2015. Review · in-vitro PMID 26236730

Clinical trial registration (ClinicalTrials.gov, as of June 2026): BPC-157 phase 2, NCT07437547 (recruiting).

Read further

Anyone who wants to see the state of the research per compound will find in the database the mechanism explanation, the studies and the evidence level of, among others, the peptides named here.

Open the database →Start with the basics: Peptides Crash Course →

This piece explains where the research stands and what the future may bring; it makes no statements about effects in humans or animals and describes no use. Facts and references verified by the Verifier, as of June 2026.

Compounds in this article

For laboratory research use only. Not for human use.